This study aimed to estimate the prevalence of overweight or obesity (Ov/Ob; BMI ≥ 25.0 kg/m2) in individuals with established ASCVD (eASCVD; included MI, stroke, and PAD) and to compare patient characteristics and clinical burden of this population to those with eASCVD and normal weight (NW; BMI 18.5 - 24.9 kg/m2). The IQVIA’s US claims-linked EHR database (2017-2022) was used to include patients with eASCVD (index date). Prevalence was calculated based on the latest BMI in the 12 months before index (baseline). Characteristics and clinical burden in the baseline period were compared among patients with eASCVD, with vs. without Ov/Ob. Of 28,021 patients with eASCVD, the prevalence of Ov/Ob was 80.7% (95% CI: 80.2%; 81.2%). Those with Ov/Ob were more frequently male (59.1% vs. 44.6%, p<0.001), had higher triglycerides (152 vs. 116 mg/dL, p<0.001) and lower HDL levels (50.3 vs. 63.1 mg/dL, p<0.001), and had a higher prevalence of several cardiometabolic comorbidities compared to those with NW (Figure 1). Among patients with eASCVD, Ov/Ob was highly prevalent, it was associated with an adverse lipid profile and increased prevalence of additional metabolic disease, including MAFLD, OSA, and type 2 diabetes. Treating excess adiposity in this population may confer benefits beyond managing ASCVD.
W. Michalak: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk, Eli Lilly and Company. N. Boame: None. X. Zhao: None. N. Lamarre: Consultant; Novo Nordisk. A. Rava: Other Relationship; Novo Nordisk. Employee; Genesis Research Group. Q.V. Doan: Consultant; Novo Nordisk, Daiichi Sankyo, Akebia Therapeutics, Inc., AbbVie Inc. M. Faurby: Employee; Novo Nordisk. B. O Hartaigh: Employee; Novo Nordisk A/S. A. Fabricatore: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. Z. Zhao: None.
